1. Medtech Insight
  2. >>Archive

FDA clears Mederi's new generator for Stretta and Secca systems

 
• By Madeleine Armstrong

The US FDA has granted 510(k) clearance for Mederi Therapeutics’ MDRF1 generator, which is used to power the firm’s Stretta and Secca systems. The former device is used to treat gastroesophageal reflux disease (GERD), while the latter treats bowel incontinence or bowel control disorder. Both devices use radiofrequency energy to remodel the valves or sphincters at either end of the digestive tract. The new generator is smaller, lighter and has a more intuitive user interface than its predecessors, Greenwich, Connecticut-based Mederi claims. Previously, the two devices were powered by two separate generators, so combining them into one could reduce costs, the company added. Mederi CE marked its next-generation Stretta and Secca systems in November (www.clinica.co.uk, 9 November 2010).

The US FDA has granted 510(k) clearance for Mederi Therapeutics’ MDRF1 generator, which is used to power the firm’s Stretta and Secca systems. The former device is used to treat gastroesophageal reflux disease (GERD), while the latter treats bowel incontinence or bowel control disorder. Both devices use radiofrequency energy to remodel the valves or sphincters at either end of the digestive tract. The new generator is smaller, lighter and has a more intuitive user interface than its predecessors, Greenwich, Connecticut-based Mederi claims. Previously, the two devices were powered by two separate generators, so combining them into one could reduce costs, the company added. Mederi CE marked its next-generation Stretta and Secca systems in November (www.clinica.co.uk, 9 November 2010).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

EU/US Trade Deal Raises Questions For Medtech

 
• By Amanda Maxwell

There is still no clarity on how life sciences will be treated in the final agreement.

NICE To Consult On UK Late-Stage Healthtech Assessments

 
• By Ashley Yeo

NICE’s three-pronged lifecycle approach to healthtech evaluations includes late-stage assessments (LSA), which will be the focus of a short consultation in August.

Roche Diagnostics Growth Flattens As China Reforms Bite; Bets On US Manufacturing, CGM For Growth

 
• By Shubham Singh

Roche has taken steps to mitigate potential tariff exposure that include shifting inventories and increasing US production of medicines. The company also initiated a tech transfer for one of its most exposed products to a US manufacturing site.